Fintel reports that on December 3, 2025, BMO Capital maintained coverage of Amgen (NasdaqGS:AMGN) with a Outperform ...

Amgen’s stock narrative is shifting, as reflected in a slight but noticeable increase in the consensus analyst price target ...

Amgen Inc. stock has reached a new 52-week high, hitting $345.95, marking a significant milestone for the biotechnology company. The stock is now trading just 0.99% from its 52-week high of $345.84.

Curious if Amgen is worth your investment dollars right now? Let’s take a clear-eyed look at where the stock stands and ...

Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.

William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA ...

According to Benzinga Pro, Amgen Inc's peer group average for short interest as a percentage of float is 6.86%, which means ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Amgen (AMGN) to $372 from $335 and keeps an Outperform rating on the shares.

Read the latest Dogs of the Dow update: see which top dividend stocks offer optimal value, growth forecasts, and safe yields.

Following the 2025 reconstitution, Schwab U.S. Dividend Equity ETF (SCHD) now has its largest sector exposure in Energy at 19 ...

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Eli Lilly and Company. Read 's Market Analysis on Investing.com ...

Overview: Sensex and Nifty traded lower on Thursday amid global uncertainties, rupee weakness, and relentless FII selling ...